Translation Control Therapeutics
New approach
New technology
New drugs

AnimaBiotech

We are pioneering Translation Control Therapeutics, a new class of drugs that specifically control protein translation

Translation Control Discovery Platform

Breakthrough Biology

Cloud Architecture

Proprietary Analysis

Translation Control Platform
We purified and fluorescently labeled all 48 types of human tRNA
Using FRET signals from signature tRNA pair(s) of the target protein, we visualize and monitor its translation
Using all 48 tRNA pairs together, we can monitor the cell’s complete protein translation activity
Using the signature pairs for its group of proteins, we can visualize and monitor the translation of a pathway
With multiple proprietary assays, our technology helps in identifying the molecular targets of translation modulating drugs
Multiple secondary assays use proprietary techniques to identify non-toxic compounds that specifically control the target’s translation
State of the art machine learning algorithms analyze billions of data points to identify translation modulating compounds
Proprietary image analysis algorithms run over millions of images to select images where the “translation light” has been affected
85% of known proteins have a “signature tRNA pair” that repeats with high frequency in their sequence but is relatively rare in the background human genome

With our technology we can visualize and specifically control the synthesis of target proteins, enabling a new strategy against many severe diseases

Translation Control Lab

Anima’s Translation Control Lab (TCL) is purpose-built for the discovery of translation modulators by integrating our proprietary technologies in biology, bioinformatics, big data image analysis and cloud software architecture

Anima Lab

PSM Assays
Screening
VPN

Cloud

Translation Data
Plate Processing
Plate Analysis
Image Analysis
PSM Image Creation
Plate Design
PSM Design
Big Data Visualisation
Bio Data Center
Big Data Analysis
• Experiment Design
• Analysis Assessment
• Bio Data Analysis
Protein Synthesis Monitoring assay, the use of labeled tRNA as FRET pairs to monitor ribosome activity in the selected cellular system
PSM assay in a selected cellular system is used to screen a small molecule library of compounds towards the identification of compounds which change the PSM signal
Unbiased scores are generated from more than 90 features extracted from images
Images captured by Operetta® are automatically uploaded to the Cloud using proprietary plate processing software
QA measures are executed to eliminate outliers wells and cells and to identify false positives
State of the art image analysis algorithms extract unique PSM and additional cellular features as a feed for the big data analysis
All images are captured by Operetta®, and the clean, calculated, PSM images is generated automatically
FRET controls, assay controls are located at specific wells in all screens, enabling strict QA algorithms
PSM design is based on proprietary mathematical algorithms analyzing the relevant RNA code
Powerful visual and analytical tools enable us to view the results online from various mathematical and biological angles
All biological data and results are kept in a customized industry standard bio data center
The analysis utilizes proprietary biological big data algorithms designed for translation control modulators discovery with high level of statistical significance

Product Pipeline

Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors) and Huntington’s Disease (monitoring mutant Huntingtin translation pausing).

Program
Assay Development
Hit Generation
Hit to lead
Preclinical
Collagen I - Target1 Lung Fibrosis
Collagen I - Target2 Liver Fibrosis
Collagen I - Target3 Scleroderma
RSV Viral Translation Inhibitors
C-Myc Oncology / Longevity
Huntingtin Huntington's disease

14 Publications

News & Events

  • Live Panel discussion with Yochi Slonim, Anima Biotech CEO

    July 11th, 2018

    Yochi Slonim will participate at the Giant Health Innovators show to discuss leading issues in healthcare tech innovation, talk about case studies illustrating successful tech innovation and implementation, and our vision for a better future where we achieve improved health outcomes at lower cost.

    The panel will take place on July 11th.

    See live panel »

  • 2018 BIO International Convention

    June 4th, 2018

    Anima Biotech will participate and present at the 2018 BIO International Convention.

    The conference is hosted by the Biotechnology Innovation Organization who represents over 1,100 biotech companies, academic institutions, state biotech centers and related organizations across the US and over 30 other nations.

    Come and see Anima’s CEO presentation on Monday 4th June.
    When: June 4th-7th
    Where: Boston, USA

    Visit the convention's website »

  • 2018 Biotech Investment showcase

    May 22nd, 2018

    Anima Biotech will participate and present at the BIOTECH INVESTMENT SHOWCASE organized by the Oxford Global Conferences Ltd.

    The 2018 Biotech Investment showcase is the UK and Europe’s most focused and leading-edge funding, investment and partnering forum in the biotech sector, hosting over 200 attendees.

    When: 22nd -23rd May 2018
    Where: London, United Kingdom

    Visit the conference's website »